Uncategorized Archives - Page 36 of 87 - PsychedelicNewsWire (PNW)

TuesdayMay 25, 2021 2:15 pm

Wesana Health, WBC Partner to Study Psychedelics as Treatment for TBIs

Daniel Carcillo retired from the National Hockey League in 2015, after nine seasons in the game. He had been diagnosed with several concussions and had struggled with insomnia, depression, anxiety, headaches and even slurred speech in his professional seasons as a hockey player. Determined to get better, Carcillo implemented lifestyle changes that included the use of psilocybin, an active ingredient found in magic mushrooms, as well as eating healthier and getting more sleep. This, he said, helped improve his overall heath tremendously. He is now dedicating his life to helping other individuals like himself as well as athletes who have…

MondayMay 24, 2021 3:00 pm

FDA Grants Authorization Allowing Research Institute to Study Psychedelic Use by Therapists

The Multidisciplinary Association for Psychedelic Studies (“MAPS”) was recently granted authorization to administer MDMA to therapists. This comes after the FDA, which gave its approval, also allowed institutes to conduct clinical trials on MDMA and its therapeutic potential in treating PTSD. The therapists, who have all volunteered, are currently undergoing training on how to treat individuals suffering from post-traumatic stress disorder and will be allowed to take part in phase 1 trials in an attempt to acquire personal experience from this treatment option. This complementary research project will be conducted by MAPS, which is also conducting phase 3 clinical trials…

MondayMay 24, 2021 1:51 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Upcoming Drug Candidate Trial Rides Swell of Groundbreaking Psychedelic Medicine Efforts

Tryp Therapeutics is a pharmaceutical company focused on developing new potential treatments for medical conditions with unmet needs The company’s current lead candidates for drug development are a synthetic psychedelic for treating fibromyalgia and eating disorders Tryp’s efforts to develop a psychedelic drug candidate are part of a broader scientific movement to use various mind-altering drugs to treat select neurological conditions when paired with the care of a trained therapist The company has been preparing to initiate a Phase 2a clinical trial for the psychedelic candidate in partnership with a medical research team at the University of Florida The idea…

FridayMay 21, 2021 2:00 pm

Core One Labs Begins Development of Psychedelic-Based Treatment for Alzheimer’s

Core One Labs Inc., a biotech and life sciences company, recently announced that its wholly owned subsidiary, Akome Biotech Ltd, has started to develop a psychedelic drug formulation indicated for Alzheimer’s treatment. The formulation, which has been dubbed ALO002, is made up of a plant bioactive and psilocybin, which is the active compound found in magic mushrooms. Researchers believe that the two ingredients are synergistic in treating the neurological disorder. The company recently filed a provisional patent application for the candidate with the United States Patent and Trademark Office. Alzheimer’s is a progressive neurologic disease that is irreversible and destroys…

ThursdayMay 20, 2021 2:00 pm

First Psychedelics Training Program Targeting Canadian Mental Health Workers Ends Successfully

ATMA Inc. has partnered with Wayfound and the PAA (a professional body bringing together all psychology professionals within Alberta province in Canada) to conduct the first-ever training program aimed at equipping licensed mental health professionals with the skills that they need to include psychedelic-assisted psychotherapy on the list of services available to patients. The training program was announced for the first time in February, and available slots quickly filled, leaving other interested professionals to join a long waitlist for the next phase of this training. This huge interest in the course underscores how much the mental health community would like…

WednesdayMay 19, 2021 3:30 pm

Psychedelics Researchers Target Systemic Inflammation

While medical science is still working to establish how different cannabinoids can best be used to combat widespread/systemic inflammation, psychedelics researchers are hard at work to develop a “wonder drug” for systemic inflammation from psychedelics. An LSU Health Sciences Center team is looking into how DOI, a synthetic psychedelic substance that is similar to LSD, can be refined in order to exploit its anti-inflammatory effects. Eleusis, a life sciences company, is working with the LSU researchers. Charles Nichols is a pharmacology professor and also the scientific founder at Eleusis. He has proven that DOI is good at not only preventing…

TuesdayMay 18, 2021 2:00 pm

Harvard Scientist Sets Out to Create Psychedelic Drugs Analogues

Jonathan Sporn, a former scientist at NIH and Harvard, has announced that his new company, Gilgamesh Pharmaceuticals, has raised a total of $27 million in its Series A funding round. The firm intends to use the money collected to prepare four drug candidates for Investigational New Drug (“IND”) applications to the FDA. This isn’t the first time that Sporn is venturing into the psychedelics sector. His first foray, through Perception Neuroscience, saw his team focus all their attention on developing a mental health drug from R-ketamine to treat depression that is unresponsive to existing medications. At the beginning of 2019,…

TuesdayMay 18, 2021 9:15 am

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Targets Potential Expansion of Rapid COVID-19 Test Kit Distribution with Delivery of 2,000 Units to Israel

XPhyto recently delivered 2,000 of its rapid Covid-ID Lab test kits to an established Israeli distributor for clinical evaluation by the Ministry of Health The delivery, which marks entry into the Middle East, follows the approval of the test kits in Europe In an earlier interview, CEO Hugh Rogers had noted that XPhyto was looking to expand distribution to various markets, including the Middle East In an interview on Proactive on March 22, XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) CEO and Director Hugh Rogers explained the implications of the CE-IVD approval (European certification) the company’s 25-minute COVID-19 RT-PCR…

MondayMay 17, 2021 3:30 pm

Texas House Passes Psychedelics Research Law

The House of Representatives in Texas passed a bill last week that would mandate the state to undertake research regarding the potential of different psychedelic substances, such as MDMA and psilocybin. The bill, whose chief sponsor was Rep. Alex Dominguez, a Democrat, was supported by 134 House members while 12 opposed it. The passage of the bill now means it heads to the state Senate for consideration. During an earlier Public Health House Committee meeting, legislators modified the scope of this expected research to cover only military veterans suffering from PTSD rather than leaving the bill with its previously wide…

FridayMay 14, 2021 2:00 pm

Maine Senate Bill Could Legalize Psilocybin Mushroom Therapy for Adults

A bill that was recently introduced in Maine will legalize psilocybin’s therapeutic use and establish a licensed industry for the drug. Psilocybin is the main active compound found in magic mushrooms. Introduced by State Sen. Donna Bailey, the Maine Psilocybin Services Act will permit individuals aged 21 and above to legally buy psilocybin products and ingest them under the supervision of psilocybin service providers who are licensed. The measure, whose purpose is to expand the access to psilocybin to help manage depression and anxiety, along with other mental health conditions, cites no specific medical diagnosis that individuals will need in…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized